These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 2846173)

  • 21. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
    Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
    Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of immune globulin in preventing complications of bone marrow transplantation: a meta-analysis.
    Bass EB; Powe NR; Goodman SN; Graziano SL; Griffiths RI; Kickler TS; Wingard JR
    Bone Marrow Transplant; 1993 Sep; 12(3):273-82. PubMed ID: 8241987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk factors for treatment failures in patients receiving PCR-based preemptive therapy for CMV infection.
    Einsele H; Hebart H; Kauffmann-Schneider C; Sinzger C; Jahn G; Bader P; Klingebiel T; Dietz K; Löffler J; Bokemeyer C; Müller CA; Kanz L
    Bone Marrow Transplant; 2000 Apr; 25(7):757-63. PubMed ID: 10745262
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
    Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-adapted pre-emptive therapy for cytomegalovirus disease in patients undergoing allogeneic bone marrow transplantation.
    Mori T; Okamoto S; Matsuoka S; Yajima T; Wakui M; Watanabe R; Ishida A; Iwao Y; Mukai M; Hibi T; Ikeda Y
    Bone Marrow Transplant; 2000 Apr; 25(7):765-9. PubMed ID: 10745263
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
    Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC
    Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized trial of high dose polyvalent intravenous immunoglobulin (HDIgG) vs. Cytomegalovirus (CMV) hyperimmune IgG in allogeneic hemopoietic stem cell transplants (HSCT).
    Zikos P; Van Lint MT; Lamparelli T; Gualandi F; Occhini D; Mordini N; Berisso G; Bregante S; Bacigalupo A
    Haematologica; 1998 Feb; 83(2):132-7. PubMed ID: 9549924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies.
    Couriel D; Canosa J; Engler H; Collins A; Dunbar C; Barrett AJ
    Bone Marrow Transplant; 1996 Aug; 18(2):347-53. PubMed ID: 8864445
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Risk factors for the occurrence of pneumonia caused by cytomegaloviruses in patients with bone marrow transplants during prevention with cytomegalovirus hyperimmune globulin].
    Schmeiser T; Heit W
    Immun Infekt; 1985 Nov; 13(6):302-6. PubMed ID: 3000924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selection of an intravenous immune globulin for the immunoprophylaxis of cytomegalovirus infections: an in vitro comparison of currently available and previously effective immune globulins.
    Chehimi J; Peppard J; Emanuel D
    Bone Marrow Transplant; 1987 Dec; 2(4):395-402. PubMed ID: 2844341
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prophylactic and therapeutic use of immunoglobulins in patients with bone marrow transplantation].
    Timár L; Kriván G; Kövesdi R
    Orv Hetil; 1994 Feb; 135(8):405-8. PubMed ID: 8139843
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Experiences with transfusion of CMV tested blood preparations after bone marrow transplantation].
    Luboldt W; Henneberg-Quester KB; Schaefer UW; Beelen DW; Quabeck K; Thraenhart O
    Beitr Infusionsther; 1990; 26():190-3. PubMed ID: 1703827
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prophylaxis and treatment of infection in the bone marrow transplant recipient.
    Winston DJ
    Curr Clin Top Infect Dis; 1993; 13():293-321. PubMed ID: 8397916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients.
    Renoult E; Clermont MJ; Phan V; Buteau C; Alfieri C; Tapiero B
    Pediatr Transplant; 2008 Jun; 12(4):420-5. PubMed ID: 18466427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
    Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
    Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interstitial pneumonia after allogeneic and autologous bone marrow transplantation.
    Funada H; Harada M; Yoshida T; Hattori K
    Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():519-30. PubMed ID: 6097710
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral prophylaxis in combined pancreas-kidney transplant recipients.
    Stratta RJ; Taylor RJ; Bynon JS; Lowell JA; Cattral MS; Frisbie K; Miller S; Radio SJ; Brennan DC
    Transplantation; 1994 Feb; 57(4):506-12. PubMed ID: 8116033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.